Aytu BioPharma vs Sunshine Biopharma
AYTU and SBFM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AYTU and SBFM compare
Aytu BioPharma is the larger company, worth 25 times as much as Sunshine Biopharma ($19.5M against $790K).
Sunshine Biopharma grew revenue faster over the last twelve months (−5.2% versus −13.3% for Aytu BioPharma).
Sunshine Biopharma keeps more of each dollar of sales as profit, with a net margin of −17.5% compared with −24.8% at Aytu BioPharma.
Sunshine Biopharma scores higher on the StockData Score (12 against 9 for Aytu BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AYTU | SBFM |
|---|---|---|
| Size and price | ||
| Market cap | $19.5M | $790K |
| Share price | $1.79 | $2.84 |
| Change, 1 year | −14.8% | −99.2% |
| Change, 5 years | −95.6% | −76.3% |
| Beta (5Y) | 1.05 | – |
| Employees | 76 | 50 |
| StockData Score | ||
| Total score | 9 | 12 (better) |
| Valuation score | 3 | 3 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 | 3 |
| Health score | 3 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× | 0.0× (better) |
| P/B | 0.6× | 0.0× (better) |
| P/FCF | 6.0× | – |
| FCF yield | 16.7% | – |
| Fair value | $8.68 | $213.99 |
| Margin of safety | 79.4% | 98.7% (better) |
| Growth | ||
| Revenue growth (TTM) | −13.3% | −5.2% (better) |
| Revenue growth, 5Y average | −2.6% | 248% (better) |
| Profitability | ||
| Gross margin | 64.0% (better) | 30.4% |
| Operating margin | −14.4% (better) | −17.2% |
| Net margin | −24.8% | −17.5% (better) |
| FCF margin | 5.6% | – |
| Return on equity | −52.6% | −23.4% (better) |
| Return on invested capital | −63.5% | −33.3% (better) |
| Financial health | ||
| Debt / equity | 0.31 (better) | 0.00 |
| Interest coverage | −4.4× | – |
| Current ratio | 1.13 | 6.47 (better) |
| Altman Z-score | −4.10 | −1.80 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 45.3% | 28.9% |
| Held by insiders | 15.1% | 24.5% |
| Short interest, % of float | 3.3% | – |
Go deeper
- AYTU stock overview
- AYTU income statement
- AYTU valuation and score
- SBFM stock overview
- SBFM income statement
- SBFM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.